Viscom (V6C) Q3 2026 earnings summary

Executive summary

• 9M 2026 order intake rose 42.4% to €90.008m and backlog increased 88.0% to €49.589m; revenue grew 5.0% to €59.615m.

• Recovery continued in Q2 and Q3, with positive quarterly EBIT; 9M EBIT improved but remained negative.

• Two major inline CT inspection contracts, particularly for battery-cell applications, are expected to contribute predominantly to FY2027 revenue.

Financial highlights

• 9M EBIT was -€0.969m versus -€1.769m; net loss widened to €2.822m from €2.309m.

• Q3 revenue was €22.667m, up 29.8% YoY; EBIT was €1.564m versus -€1.821m, and net profit was €0.980m versus a €1.635m loss.

• Material costs rose to €26.181m from €21.369m; staff costs were broadly stable at €26.242m versus €26.321m, while other operating expenses fell to €8.874m from €9.060m.

• Financial expenses increased to €1.760m from €1.562m; income tax was an expense of €0.095m versus income of €1.020m, including a prior-year tax benefit from loss carryforwards.

Outlook and guidance

• FY2026 guidance: revenue €80m–€90m, order intake €100m–€110m, EBIT €1.6m–€4.5m and EBIT margin 2%–5%; order-intake guidance was raised in October and subsequently confirmed.

• No further major contracts are currently expected in Q4 2026; major CT inspection contracts secured in Q2 and Q3 are expected to contribute predominantly in FY2027.

• Efficiency programs are intended to support profitable growth in 2027; demand in Asia and the Americas is expected to remain supportive.

• Liquidity is expected to be supported by internal resources and available credit facilities; additional financing needs depend on economic conditions, and government grants are being assessed.